The genetics and immunopathogenesis of inflammatory bowel disease

Nature Reviews Immunology

Volumn 8, Issue 6, 2008, Pages 458-466

  Cho, Judy H ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DEFENSIN; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.3;

AUTOPHAGY; COMPARATIVE STUDY; CROHN DISEASE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC VARIABILITY; GOBLET CELL; HAPLOTYPE MAP; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTESTINE CRYPT; LAMINA PROPRIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 44349124113     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2340     Document Type: Review

References (97)

1. Podolsky, D. K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002).
2. Loftus, E. V. Jr Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
3. Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434 (2007).
4. Elson, C. O. et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 206, 260-276 (2005).
5. Frazer, K. A. et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851-861 (2007). Data from the HapMap project provided the basis for the advent of GWA studies.
6. Wang, W. Y., Barratt, B. J., Clayton, D. G. & Todd, J. A. Genome-wide association studies: theoretical and practical concerns. Nature Rev. Genet. 6, 109-118 (2005).
7. Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases and complex traits. Nature Rev. Genet. 6, 95-108 (2005).
8. Cho, J. H. & Weaver, C. T. The genetics of inflammatory bowel disease. Gastroenterology 133, 1327-1339 (2007).
9. Binder, V. Genetic epidemiology in inflammatory bowel disease. Digest. Dis. 16, 351-355 (1998).
10. Fisher, S. A. et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genet. 27 April 2008 (doi:10.1038/ng.145).
11. Franke, A. et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nature Genet. 27 April 2008 (doi:10.1038/ng.148). Together with reference 10, this study identifies an overlap between susceptibility loci in Crohn's disease and ulcerative colitis.
12. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007). A landmark article defining the GWAs for seven common diseases, including Crohn's disease.
13. Tarlinton, D., Light, A., Metcalf, D., Harvey, R. P. & Robb, L. Architectural defects in the spleens of Nkx2-3-deficient mice are intrinsic and associated with defects in both B cell maturation and T cell-dependent immune responses. J. Immunol. 170, 4002-4010 (2003).
14. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
15. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
16. Girardin, S. E. et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 278, 41702-41708 (2003).
17. Inohara, N. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278, 5509-5512 (2003).
18. Kobayashi, K. S. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731-734 (2005).
19. Croucher, P. J. et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. 11, 6-16 (2003).
20. Leong, R. W. et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol. Ther. 17, 1465-1470 (2003).
21. Yamazaki, K., Takazoe, M., Tanaka, T., Kazumori, T. & Nakamura, Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J. Hum. Genet. 47, 469-472 (2002).
22. Kugathasan, S. et al. Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease. Inflamm. Bowel Dis. 11, 631-638 (2005).
23. Economou, M., Trikalinos, T. A., Loizou, K. T., Tsianos, E. V. & Ioannidis, J. P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol. 99, 2393-2404 (2004).
24. Abraham, C. & Cho, J. H. Functional consequences of NOD2 (CARD15) mutations. Inflamm. Bowel Dis. 12, 641-650 (2006).
25. Hugot, J. P. et al. Prevalence of CARD15/NOD2 mutations in caucasian healthy people. Am. J. Gastroenterol. 102, 1259-1267 (2007).
26. Pauleau, A. L. & Murray, P. J. Role of nod2 in the response of macrophages to Toll-like receptor agonists. Mol. Cell Biol. 23, 7531-7539 (2003).
27. Schreiber, S., Nikolaus, S. & Hampe, J. Activation of nuclear factor κB inflammatory bowel disease. Gut 42, 477-484 (1998).
28. Hedl, M., Li, J., Cho, J. H. & Abraham, C. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc. Natl Acad. Sci. USA 104, 19440-19445 (2007).
29. Watanabe, T. et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118, 545-559 (2008).
30. Hisamatsu, T. et al. CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 124, 993-1000 (2003).
31. Kim, Y. G. et al. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity 28, 246-257 (2008).
32. Wehkamp, J. et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl Acad. Sci. USA 102, 18129-18134 (2005).
33. Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127, 412-421 (2004).
34. Simms, L. A. et al. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 27 February 2008 (doi:10.1136/gut.2007.142588).
35. Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genet. 39, 207-211 (2007).
36. Mizushima, N. et al. Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate. J. Cell Sci. 116, 1679-1688 (2003).
37. Rioux, J. D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genet. 39, 596-604 (2007).
38. Levine, B. & Deretic, V. Unveiling the roles of autophagy in innate and adaptive immunity. Nature Rev. Immunol. 7, 767-777 (2007).
39. Amano, A., Nakagawa, I. & Yoshimori, T. Autophagy in innate immunity against intracellular bacteria. J. Biochem. 140, 161-166 (2006).
40. Parkes, M. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genet. 39, 830-832 (2007).
41. Collazo, C. M. et al. Inactivation of LRG-47 and IRG-47 reveals a family of interferon γ-inducible genes with essential, pathogen-specific roles in resistance to infection. J. Exp. Med. 194, 181-188 (2001).
42. Singh, S. B., Davis, A. S., Taylor, G. A. & Deretic, V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 313, 1438-1441 (2006).
43. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996). A seminal article describing the distinct cytokine profiles that distinguish Crohn's disease from ulcerative colitis.
44. Plevy, S. E. et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. 159, 6276-6282 (1997).
45. Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-3 (2006). Initial description of association of variants in IL23R with a common, complex inflammatory disorder.
46. Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290 (2007).
47. Burton, P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genet. 39, 1329-1337 (2007).
48. Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70 (2003).
49. Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699-5708 (2002). A seminal article identifying IL23R, its expression, its signalling pathway and its relationship to IL-12R signalling pathways.
50. H17 lineage. Nature 441, 231-234 (2006).
51. Palmer, M. T. & Weaver, C. T. Immunology: narcissistic helpers. Nature 448, 416-418 (2007).
52. + T helper cells. Cell 126, 1121-1133 (2006).
53. H17 and regulatory T cells. Nature 441, 235-238 (2006).
54. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006).
55. Wiekowski, M. T. et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J. Immunol. 166, 7563-7570 (2001).
56. Elson, C. O. et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132, 2359-2370 (2007).
57. Hue, S. et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473-2483 (2006).
58. Kullberg, M. C. et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203, 2485-2494 (2006).
59. Uhlig, H. H. et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309-318 (2006).
60. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310-1316 (2006).
61. Mannon, P. J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
62. Watford, W. T. et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202, 139-156 (2004).
63. Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371-381 (2007).
64. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunol. 8, 967-974 (2007).
65. Barrett, J. C. et al. Genome-wide association defines more than thirty distinct susceptibility loci for Crohn's disease. Nature Genet. (in the press).
66. Fuss, I. J. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12, 9-15 (2006).
67. Schmidt, C. et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11, 16-23 (2005).
68. Stallmach, A. et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int. J. Colorectal Dis. 19, 308-315 (2004).
69. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
70. Wolk, K. et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J. Immunol. 178, 5973-5981 (2007).
71. Sugimoto, K. et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534-544 (2008).
72. Becker, C. et al. Cutting Edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177, 2760-2764 (2006).
73. Wilson, N. J. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunol. 8, 950-957 (2007).
74. Silverberg, M. S. et al. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease. Eur. J. Hum. Genet. 15, 328-335 (2007).
75. Libioulle, C. et al. A novel susceptibility locus for Crohn's disease identified by whole genome association maps to a gene desert on chromosome 5p13.1 and modulates the level of expression of the prostaglandin receptor EP4. PLoS Genet. 3, e58 (2007).
76. Kabashima, K. et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883-893 (2002).
77. Peltekova, V. D. et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nature Genet. 36, 471-475 (2004).
78. Altshuler, D. et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genet. 26, 76-80 (2000).
79. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
80. Remmers, E. F. et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357, 977-986 (2007).
81. Lowe, C. E. et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genet. 39, 1074-82 (2007).
82. Hafler, D. A. et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851-862 (2007).
83. Loftus, E. V. Jr et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 114, 1161-1168 (1998).
84. Loftus, E. V. Jr et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 46, 336-343 (2000).
85. Bernstein, C. N., Blanchard, J. F., Rawsthorne, P. & Wajda, A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am. J. Epidemiol. 149, 916-924 (1999).
86. Sandler, R. S. in Inflammatory bowel disease: from bench to bedside (eds Targan, S. R. & Shanahan, F.) 5-30 (Williams and Wilkins, Baltimore, 1994).
87. Calkins, B. M. & Mendelhoff, A. I. in Inflammatory Bowel Disease (eds Kirsner, J. B. & Shorter, R. G.) 31-68 (Williams & Wilkins, Baltimore, 1995).
88. Yang, H. & Rotter, J. I. in Inflammatory bowel disease: from bench to bedside (eds Targan, S. R. & Shanahan, F.) 32-64 (Williams and Wilkins, Baltimore, 1994).
89. Ogunbi, S. O., Ransom, J. A., Sullivan, K., Schoen, B. T. & Gold, B. D. Inflammatory bowel disease in African-American children living in Georgia. J. Pediatr. 133, 103-107 (1998).
90. Binder, V. Genetic epidemiology in inflammatory bowel disease. Digest. Dis. 16, 351-355 (1998).
91. Yang, H. & Rotter, J. I. in Inflammatory Bowel Disease (eds Kirsner, J. B. & Shorter, R. G.) 301-331 (Williams & Wilkins, Baltimore, 1995).
92. Tysk, C., Lindberg, E., Jarnerot, G. & Floderus-Myrhed, B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29, 990-996 (1988).
93. Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E. & Jarnerot, G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124, 1767-1773 (2003).
94. Thompson, N. P., Driscoll, R., Pounder, R. E. & Wakefield, A. J. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 312, 95-96 (1996).
95. Orholm, M., Binder, V., Sorensen, T. I., Rasmussen, L. P. & Kyvik, K. O. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand. J. Gastroenterol. 35, 1075-1081 (2000).
96. Gent, A. E., Hellier, M. D., Grace, R. H., Swarbrick, E. T. & Coggon, D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 343, 766-767 (1994).
97. Boyko, E. J., Koepsell, T. D., Perera, D. R. & Inui, T. S. Risk of ulcerative colitis among former and current cigarette smokers. N. Engl. J. Med. 316, 707-710 (1987).